News | August 04, 2021
Dr Reddy’s relaunch Naproxen Sodium Tablets in the US
It is part of the company’s pain/analgesics portfolio of OTC products
It is part of the company’s pain/analgesics portfolio of OTC products
Startup receives US $ 5 million in first round of funding
_logo_256_384.jpg){kind=logo}
It supports sequencing-based COVID 19 surveillance in India
Arch Pharma Labs has filed the application
Five seats reserved for Wards of COVID warriors in central MBBS admission
Complementary business models are the reason for the acquisition
India business is growing as per projections; whereas US business will bounce back soon.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
Subscribe To Our Newsletter & Stay Updated
